199 related articles for article (PubMed ID: 24022345)
1. Development and characterisation of ursolic acid nanocrystals without stabiliser having improved dissolution rate and in vitro anticancer activity.
Song J; Wang Y; Song Y; Chan H; Bi C; Yang X; Yan R; Wang Y; Zheng Y
AAPS PharmSciTech; 2014 Feb; 15(1):11-19. PubMed ID: 24022345
[TBL] [Abstract][Full Text] [Related]
2. Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation.
Wang Y; Song J; Chow SF; Chow AH; Zheng Y
Int J Pharm; 2015 Oct; 494(1):479-89. PubMed ID: 26302857
[TBL] [Abstract][Full Text] [Related]
3. Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size.
Pi J; Liu Z; Wang H; Gu X; Wang S; Zhang B; Luan H; Zhu Z
Curr Drug Deliv; 2016; 13(8):1358-1366. PubMed ID: 26953239
[TBL] [Abstract][Full Text] [Related]
4. Ursolic acid nanoparticles for oral delivery prepared by emulsion solvent evaporation method: characterization, in vitro evaluation of radical scavenging activity and bioavailability.
Qiu L; Zhao X; Zu Y; Zhang Y; Liu Y; Wu W; Li Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):610-621. PubMed ID: 30831030
[TBL] [Abstract][Full Text] [Related]
5. Ursolic Acid Loaded PLGA Nanoparticles: in vitro and in vivo Evaluation to Explore Tumor Targeting Ability on B16F10 Melanoma Cell Lines.
Baishya R; Nayak DK; Kumar D; Sinha S; Gupta A; Ganguly S; Debnath MC
Pharm Res; 2016 Nov; 33(11):2691-703. PubMed ID: 27431865
[TBL] [Abstract][Full Text] [Related]
6. Preparation of ursolic acid-phospholipid complex by solvent-assisted grinding method to improve dissolution and oral bioavailability.
Wang W; Zhang W; Jiang Y; Wang X; Zhang X; Liu H; Zhang T
Pharm Dev Technol; 2020 Jan; 25(1):68-75. PubMed ID: 31544585
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies.
Parveen R; Ahmad FJ; Iqbal Z; Samim M; Ahmad S
Drug Dev Ind Pharm; 2014 Sep; 40(9):1206-12. PubMed ID: 23826860
[TBL] [Abstract][Full Text] [Related]
8. Solid dispersion of ursolic acid in Gelucire 50/13: a strategy to enhance drug release and trypanocidal activity.
de Oliveira Eloy J; Saraiva J; de Albuquerque S; Marchetti JM
AAPS PharmSciTech; 2012 Dec; 13(4):1436-45. PubMed ID: 23070562
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of betulin nanoparticles for oral hypoglycemic drug by antisolvent precipitation.
Zhao X; Wang W; Zu Y; Zhang Y; Li Y; Sun W; Shan C; Ge Y
Drug Deliv; 2014 Sep; 21(6):467-79. PubMed ID: 24479653
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Novel Ursolic acid Derivatives as Potential Anticancer Prodrugs.
Yang X; Li Y; Jiang W; Ou M; Chen Y; Xu Y; Wu Q; Zheng Q; Wu F; Wang L; Zou W; Zhang YJ; Shao J
Chem Biol Drug Des; 2015 Dec; 86(6):1397-404. PubMed ID: 26077799
[TBL] [Abstract][Full Text] [Related]
11. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
[TBL] [Abstract][Full Text] [Related]
12. Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (ε-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo.
Zhang H; Zheng D; Ding J; Xu H; Li X; Sun W
Int J Nanomedicine; 2015; 10():1909-20. PubMed ID: 25792825
[TBL] [Abstract][Full Text] [Related]
13. Discovery of FZU-03,010 as a self-assembling anticancer amphiphile for acute myeloid leukemia.
Chen Y; Li C; Zheng Y; Gao Y; Hu J; Chen H
Bioorg Med Chem Lett; 2017 Feb; 27(4):1007-1011. PubMed ID: 28073673
[TBL] [Abstract][Full Text] [Related]
14. Poly(lactic acid) nanoparticles loaded with ursolic acid: Characterization and in vitro evaluation of radical scavenging activity and cytotoxicity.
Antônio E; Antunes ODR; de Araújo IS; Khalil NM; Mainardes RM
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():156-166. PubMed ID: 27987693
[TBL] [Abstract][Full Text] [Related]
15. Triple Strategies to Improve Oral Bioavailability by Fabricating Coamorphous Forms of Ursolic Acid with Piperine: Enhancing Water-Solubility, Permeability, and Inhibiting Cytochrome P450 Isozymes.
Yu D; Kan Z; Shan F; Zang J; Zhou J
Mol Pharm; 2020 Dec; 17(12):4443-4462. PubMed ID: 32926628
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
[TBL] [Abstract][Full Text] [Related]
17. Enhanced bioavailability and hepatoprotectivity of optimized ursolic acid-phospholipid complex.
Biswas S; Mukherjee PK; Harwansh RK; Bannerjee S; Bhattacharjee P
Drug Dev Ind Pharm; 2019 Jun; 45(6):946-958. PubMed ID: 30767678
[TBL] [Abstract][Full Text] [Related]
18. Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents.
Chen H; Gao Y; Wang A; Zhou X; Zheng Y; Zhou J
Eur J Med Chem; 2015 Mar; 92():648-55. PubMed ID: 25617694
[TBL] [Abstract][Full Text] [Related]
19. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.
Morakul B; Suksiriworapong J; Chomnawang MT; Langguth P; Junyaprasert VB
Eur J Pharm Biopharm; 2014 Nov; 88(3):886-96. PubMed ID: 25201298
[TBL] [Abstract][Full Text] [Related]
20. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
